Clinical Trial Update: A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and efficacy of ganciclovir (DHPG) for symptomatic central nervous system involvement in congenital cytomegalovirus infect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Cytomegalovirus Infection

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Infections | Phase 3 | Status: COMPLETED